Search Results
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
PK profiling and evaluation of metabolic, glycemic, lipid, and body composition measures, including weight, waist circumference, and body mass index (BMI), and other cardiometabolic measures.For more information on this clinical trial, please visit:
More news about: MetaVia Inc.
Apr 09, 2026, 08:30 ET Underneath the Lost Kilos: Muscle Composition, Preservation and Function, Upcoming Webinar Hosted by Xtalks
TORONTO, April 9, 2026 /PRNewswire/ -- Weight loss is complex. Traditional metrics like kilograms lost and BMI tell only part of the story. The next era of obesity trials demands evidence that goes underneath the lost kilos, evidence that differentiates therapies,
More news about: Xtalks
Apr 08, 2026, 13:02 ET THEODORE SHAPIRO TO BE NAMED A BMI ICON AT THE 2026 BMI FILM, TV AND VISUAL MEDIA AWARDS
BMI® will honor Emmy® award-winning composer Theodore Shapiro with the BMI Icon Award at the 2026 BMI Film, TV and Visual Media Awards on May 13th in Beverly
More news about: Broadcast Music, Inc. (BMI)
Apr 08, 2026, 12:15 ET ANGEL TO EXCLUSIVELY STREAM BUTCH HARTMAN STUDIOS' THE GARDEN CARTOON SEASON 2
Butch Hartman Studios: An inaugural member of Animation Magazine's Hall of Fame, Butch Hartman is a multiple Emmy® and ANNIE Award®-nominated and BMI Award-winning animator, writer, director, producer, illustrator, and actor who has been entertaining and inspiring kids and families for four decades.
More news about: Butch Hartman Studios; Angel
Apr 08, 2026, 02:30 ET Rock Tech Lithium and BMI Group Establish CAD $200 Million Anchor Partnership to Advance Red Rock Lithium Converter in Canada
(TSX-V: RCK) (OTCQX: RCKTF) (FWB: RJIB) (WKN: A1XF0V) (the "Company" or "Rock Tech") is pleased to announce a strategic partnership with the BMI Group Inc. ("the BMI Group"), a Canadian industrial infrastructure platform company, to develop Rock Tech's lithium converter facility in Red Rock, Ontario, Canada
More news about: Rock Tech Lithium Inc.
Apr 07, 2026, 12:13 ET LEGENDARY, PROLIFIC SINGER-SONGWRITER PAUL ANKA TO RECEIVE THE BMI ICON AWARD AT THE 2026 BMI POP AWARDS
BMI announced today that prolific singer-songwriter and performer Paul Anka will receive the BMI Icon Award at the 2026 BMI Pop Awards on May 12 at Beverly Wilshire in Beverly
More news about: Broadcast Music, Inc. (BMI)
Apr 07, 2026, 09:56 ET Duchesnay launches a contraceptive vaginal system that can be used for up to a full year
women of reproductive potential to prevent pregnancy. PrRingzaTM has not been adequately studied in women with a Body Mass Index (BMI) > 29.0 kg/m2.The efficacy and safety of PrRingzaTM for use in contraception were demonstrated in two pivotal
More news about: Duchesnay inc.
Apr 07, 2026, 09:00 ET Rightway Launches Care Complete Weight Management to Help Employers Maximize GLP-1 Investment
investment. According to Rightway's 2025 employer survey of 200 benefits leaders at large self-insured companies, 83% want comprehensive outcomes data like BMI changes and health improvements, but most lack access to it today. Meanwhile, employers want integrated solutions that deliver both the clinical guidance
More news about: Rightway
Apr 07, 2026, 08:00 ET Novo Nordisk's Wegovy® HD available now nationwide
semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention.1,2 1,407 adults with BMI ≥30 kg/m2 without diabetes were included in the trial. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against
More news about: NOVO NORDISK INC.
Apr 06, 2026, 09:00 ET Normani Unveils Second Drop of NORMANI Collection Exclusively on SHEIN
– the latter of which ascended to #1 on Billboard's Mainstream R&B/Hip-Hop charts. In between tallying billions of streams, she has garnered six BMI Awards, two iHeartRadio Music Awards, an MTV Video Music Award, a Variety Hitmaker Award, and a Soul Train Music Award. Most recently, after much anticipation,
More news about: SHEIN
Apr 02, 2026, 08:00 ET Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
tolerability of oral semaglutide 25 mg (OASIS 4 trial data) versus orforglipron 36 mg (ATTAIN-1 trial data) in adults with obesity (BMI>=30 kg/m2), or overweight (BMI >=27 kg/m2) and at least one weight-related comorbidity without diabetes. A simulated treatment comparison (STC)
More news about: NOVO NORDISK INC.
Apr 02, 2026, 08:00 ET Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
tolerability of oral semaglutide 25 mg (OASIS 4 trial data) versus orforglipron 36 mg (ATTAIN-1 trial data) in adults with obesity (BMI>=30 kg/m2), or overweight (BMI >=27 kg/m2) and at least one weight-related comorbidity without diabetes. A simulated treatment comparison (STC)
More news about: NOVO NORDISK INC.
Apr 02, 2026, 02:41 ET StairMed Secures RMB 500 Million Financing Led by Alibaba, Joined by Tencent
Trials for BMI Systems Set for Mid-2026, Neuromodulation Pipeline AdvancesWith the closing of this financing round, StairMed plans to accelerate development of its technology platform and clinical programs, building on three successful clinical implants of its brain-machine interface (BMI) system
More news about: StairMed
Mar 31, 2026, 09:02 ET New study demonstrates feasibility and safety of deprescribing diabetes medications when lifestyle medicine is integrated into primary care
outcome."Among patients who were deprescribed and had follow‑up data available, clinically meaningful improvements were observed. Average body mass index (BMI) decreased by 2.2 kg/m², and average blood glucose levels fell by 50.5 mg/dL, both statistically significant changes.The most common
More news about: American College of Lifestyle Medicine
Mar 31, 2026, 08:00 ET Snoring and Sleep Apnea Accelerate Vascular Aging
that habitual snoring and night-to-night variability in sleep-disordered breathing may contribute to vascular risk independently of age, sex, and BMIADELAIDE, Australia and ISSY-LES-MOULINEAUX, France, March 31, 2026
More news about: Withings
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
life, cardiometabolic health and inflammation. In addition, Taltz plus Zepbound was associated with nominally statistically significant improvements in BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides, and total cholesterol versus Taltz monotherapy. "In TOGETHER-PsA, treating
More news about: Eli Lilly and Company
Mar 27, 2026, 09:00 ET UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
years*Consistency across patient populations: BIMZELX demonstrated efficacy improvements over three years across HS population subgroups, including BMI, age, disease duration, sex, and disease severity in a post hoc analysis *ATLANTA, March
More news about: UCB
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
supporting a shift in obesity treatment, redefining healthy weight loss as the achievement of an optimal body composition rather than simply an optimal BMI.Lead clinical candidate targeting sarcopenia/sarcopenic obesity and aging-related disease. Eos's lead program, PTC-2105, is a
More news about: Pulmatrix Inc.
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
injection once weekly for 78 weeks. The trial enrolled approximately 1,000 adults with type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2). Enrolled patients have been randomized to one of four weekly treatment arms: VK2735 7.5 mg, 12.5 mg,
More news about: Viking Therapeutics, Inc.
Mar 19, 2026, 12:04 ET FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
once-weekly Wegovy® 7.2 mg compared to placebo and Wegovy® 2.4 mg, as an adjunct to lifestyle intervention in 1,407 adults with obesity (BMI 30 kg/m2 or greater), without diabetes.1,3
More news about: NOVO NORDISK INC.
Mar 19, 2026, 06:45 ET Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Percentage change in body weight at 40 weeks from a baseline of 96.9 kg (213.6 lbs; BMI of 35.8 kg/m2) Efficacy estimand
More news about: Eli Lilly and Company
Mar 18, 2026, 16:57 ET Carrot Presents AI-Powered Metabolic-Fertility Research at National Conference on Women's Health Hosted by the U.S. Department of Health and Human Services
demand for a scalable preconception metabolic intervention. Among current Sprints users planning to conceive, the mean age is 34 years and the mean BMI is 30.4, consistent with Class I obesity.Early engagement is strong. 92% of members who are recommended a Sprint as part of their Carrot Plan
More news about: Carrot Fertility, Inc.
Mar 18, 2026, 09:00 ET CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End
Collab aims to:Reduce preventable hospitalizationsImprove key health outcomes, including blood pressure, cholesterol and BMIConnect residents to integrated medical, nutrition, and social servicesDecrease food insecurity in the Historic West End (HWE)Expand
More news about: CVS Health
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
PK profiling and evaluation of metabolic, glycemic, lipid, and body composition measures, including weight, waist circumference, and body mass index (BMI), and other cardiometabolic measures."This IRB approval marks a key milestone in the advancement of DA-1726 and builds on the program's increasingly
More news about: MetaVia Inc.
Mar 12, 2026, 09:05 ET BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
improvements compared to untreated children, which is particularly relevant in early life. Researchers also saw significant improvements in body mass index (BMI) in children who initiated treatment when compared to untreated children."It is encouraging to see increasing data on outcomes beyond height,
More news about: BioMarin Pharmaceutical Inc.